ERCC1基因多态性对晚期结直肠癌患者奥沙利铂化疗敏感性的相关性研究.docVIP

精品论文 参考文献 ERCC1基因多态性对晚期结直肠癌患者奥沙利铂化疗敏感性的相关性研究 马金华 骆玉霜 沈存芳 　　青海大学医学院附属医院肿瘤内科 青海西宁 810001 　　【摘要】目的:探讨切除修复交叉互补基因 1 （ERCC1） Asn118Asn Crarr;T, rs11615 多态性与晚期结直肠癌患者对奥沙利铂为主方案一线化疗疗效的关系。方法:108例晚期结直肠癌患者采静脉血提取DNA,以 real-time PCR法对 ERCC1基因进行 SNP分型。患者接受奥沙利铂为主方案化疗,观察疾病有效率（CR +PR）及肿瘤进展时间 （TTP） ,比较不同基因型与其有效率的关系。结果:108例入组患者总有效率为 565%(61/108),其中ERCC1基因进行SNP分型，纯合基因型（C/C）与杂合基因型（C/T +T/T）在疾病有效组和无效组之间分布有统计学意义(chi;2=7959， P=0005)。入组患者总中位 TTP为 6个月 , C/T +T/T基因型患者中位TTP为6个月,与C/C中位TTP 7个月相比,差异有统计学意义（chi;2=24247P=0039）。结论:ERCC1 Asn118Asn基因多态性与晚期结直肠癌患者接受奥沙利铂为主方案一线化疗的临床疗效有相关性,有待进一步临床研究。 　　【关键词】晚期结直肠癌; 　基因多态性; 　ERCC1; 　奥沙利铂Research on the clinical outcome of advanced colorectal cancer treated with oxaliplatin influenced by ERCC1 gene polymorphism in peripheral blood 　　Ma JinghuaLuo YuxiangShen Cunfang 　　【Abstract】　Objective:To assess the effect of the polymorphism of ERCC1Asn118Asn(Crarr;T, rs11615)on treatment response and TTP of advanced colorectal cancer patients treated with oxaliplatin as first-line chemotherapy regimen. Methods:DNA was extractedrom peripheral venous blood from 108 advanced colorectal cancerr patients. Real-time PCR was used for genotyping.ERCC1 genotypes were analyzed for associations with response rate(RR)and time to progression(TTP). Results:The RR of cases was 565% . In this subgroup, patients with C/C genotype did show distinct lypreponderance compared to those with C/T+T/T,(X27959， P =0005).The median TTP for all 108 patients was 6 months, patients possessing C/C genotype showed a median TTP of 7 months, was different from 6 months in patients with C/T+T/T genotype(OR =24247, P =0039). Conclusion:The results suggest that the ERCC1 Asn118Asn genetic polymorphisms may be associated with clinical outcomes of patients with advanced colorectal cancerr accepted oxaliplatin as first-line chemotherapy, but need further observation and demonstration. 　　【Keywords】Colorectal cancer; 　Gene polymorphism; 　Pharmacogenetics; 　Excision repair cross-complementation group 1